These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11023329)

  • 1. Optimal age for starting lipid lowering treatment. Adjusted date do not justify a lower optimal age.
    Jackson PR; Wallis EJ; Ramsay LE
    BMJ; 2000 Sep; 321(7261):637-8. PubMed ID: 11023329
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.
    Simpson WG; Twomey P
    BMJ; 2000 Sep; 321(7261):637; author reply 638. PubMed ID: 11023327
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal age for starting lipid lowering treatment. It is more efficient to screen and treat elderly people.
    Marshall T
    BMJ; 2000 Sep; 321(7261):637; author reply 638. PubMed ID: 11023328
    [No Abstract]   [Full Text] [Related]  

  • 4. The evidence for lipid lowering: type 2 diabetes and coronary heart disease risk.
    Townsend D; Davis R
    Prof Nurse; 2004 Jun; 19(10):38-40. PubMed ID: 15233071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering strategies. Today's therapies and co-therapies can reduce CHD risk.
    McDonald K
    Adv Nurse Pract; 2003 Dec; 11(12):24-8; quiz 28-9. PubMed ID: 14689742
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
    Mosca LJ
    Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
    Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications.
    Chiuve SE; McCullough ML; Sacks FM; Rimm EB
    Circulation; 2006 Jul; 114(2):160-7. PubMed ID: 16818808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.
    EUROASPIRE II Study Group
    Eur Heart J; 2001 Apr; 22(7):554-72. PubMed ID: 11259143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of statins. But New Zealand tables are better.
    McLeod AJ; Armitage M
    BMJ; 1998 Aug; 317(7156):474. PubMed ID: 9758472
    [No Abstract]   [Full Text] [Related]  

  • 13. [Disordered lipid metabolism--current diagnostics].
    Schwandt P
    MMW Fortschr Med; 2003 Mar; 145(13):26-7. PubMed ID: 15101528
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study.
    James P; Tan HH; MacAlpine R; Brennan G; Emslie-Smith A; Morris AD
    Diabet Med; 2004 Oct; 21(10):1108-12. PubMed ID: 15384958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment and management of lipid disorders in men.
    Haines CA; Collins LG; Nimoityn P
    Prim Care; 2006 Mar; 33(1):93-114, ix. PubMed ID: 16516682
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New options in lipid management--can we extend the benefits of current therapy? Introduction.
    Gotto AM; Paoletti R
    Am Heart J; 2002 Dec; 144(6 Suppl):S19-20. PubMed ID: 12486411
    [No Abstract]   [Full Text] [Related]  

  • 20. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.